Merck: successful Phase III trial for Keytruda

(CercleFinance.com) - Merck announces that a Phase 3 clinical trial evaluating Keytruda (pembrolizumab) as a peri-operative treatment for patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) had met its primary objective of event-free survival (EFS).


The study administered Keytruda as neoadjuvant therapy, followed by a combination with standard radiotherapy as adjuvant therapy, and then Keytruda as maintenance therapy, compared with adjuvant radiotherapy alone.

Interim results showed a 'statistically significant and clinically relevant' improvement in EFS.

In addition, a significant improvement in major pathological response was observed in the Keytruda group.

Copyright (c) 2024 CercleFinance.com. All rights reserved.